Skip to NavigationSkip to content

Teva terminates Ajovy at Phase 3 in episodic cluster headache

Published on 24/04/19 at 09:57am

Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) in the treatment of episodic cluster headaches after it became apparent that the drug is unlikely to meet its primary endpoint at Phase 3.

Conclusions drawn from a pre-specified futility analysis of the Phase 3 ENFORCE study indicated that Ajovy would not adequately improve mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period, so the drugmaker has decided to discontinue the trial.

Despite the decision, Teva made clear that it would still pursue other applications of Ajovy, particularly in the treatment of post-traumatic headache, which is currently being evaluated at Phase 2.

“We’d like to thank the patients and investigators for their immense contributions to this study,” remarked Dr Tushar Shah, Senior Vice President, Head of Global Specialty Clinical Development at Teva. “Despite these results, we are continuing to evaluate if fremanezumab treatment can provide clinical benefits in additional diseases where anti-calcitonin gene-related peptide (CGRP) therapy may play a role in its pathophysiology.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches